lung disease

Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.

The ALARM Partnership is being launched to measure the impact of AlloSure and RemoTraC on lung transplant patients.

The researchers' findings suggest that methylation at those sites might have their effect on lung function through its effect on smoking behaviors.

With RNA sequence data on thousands of individual lung cells, researchers fleshed out new and known cell clusters, before digging into cell state and cellular interaction changes in asthma.

The test is based on RNA sequencing and is used to differentiate between idiopathic pulmonary fibrosis and other lung diseases in order to avoid surgery.

The study supports the use of Envisia to help with the diagnosis of idiopathic pulmonary fibrosis, particularly in patients without a clear radiological result.

The LCD will enable coverage of Envisia in patients for whom imaging does not lead to a definitive diagnosis of idiopathic pulmonary fibrosis.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.